NASDAQ:CMPX Compass Therapeutics Q2 2026 Earnings Results & Report $0.88 +0.02 (+2.57%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$0.86 -0.02 (-1.93%) As of 04:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Compass Therapeutics missed analyst earnings expectations in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.13 versus the -$0.1107 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 6, 2026TimeBefore Market OpensConference Call7:30 AM ET Compass Therapeutics EPS ResultsActual EPS-$0.13Consensus EPS -$0.1107Beat/MissMissed by -$0.0193One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersCompass Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue($0.60) millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCompass Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Compass Therapeutics Q2 2026 Earnings FAQ Did Compass Therapeutics beat earnings estimates for Q2 2026? Compass Therapeutics (NASDAQ:CMPX) reported earnings of -$0.13 per share for Q2 2026, missing the consensus estimate of -$0.1107. The report was announced on Thursday, August 6, 2026. When is Compass Therapeutics' next earnings date? Compass Therapeutics' next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Compass Therapeutics on the company's earnings history page. Compass Therapeutics Earnings HeadlinesCompass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 14 at 4:30 PM | globenewswire.comCompass Therapeutics (CMPX) Stock Fair Value Falls After Tovecimig Regulatory ConcernsOctober 13 at 12:57 AM | finance.yahoo.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.October 15 at 1:00 AM | Decentralized Masters (Ad)Contrasting HCW Biologics (NASDAQ:HCWB) & Compass Therapeutics (NASDAQ:CMPX)October 7, 2026 | americanbankingnews.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Stock Has Consensus Price Target of $10.21October 4, 2026 | americanbankingnews.comCompass Therapeutics consensus price target decreased by 33.73% to $6.03October 2, 2026 | msn.comSee More Compass Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Compass Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Compass Therapeutics and other key companies, straight to your email. Email Address About Compass TherapeuticsCompass Therapeutics (NASDAQ:CMPX) is a clinical-stage biotechnology company focused on developing antibody-based immunotherapies for the treatment of cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving anti-tumor responses and addressing limitations associated with existing cancer treatments. Compass Therapeutics’ pipeline has included CTX-471, an investigational agonist antibody targeting CD137, also known as 4-1BB. The therapy is designed to stimulate immune cells involved in tumor recognition and destruction and has been investigated in combination with other immuno-oncology treatments. The company has also pursued additional antibody programs intended to modulate immune signaling and support the development of combination therapies. Headquartered in Boston, Massachusetts, Compass Therapeutics conducts research and development activities primarily in the United States. As a clinical-stage company, its programs remain under development and may require additional clinical testing and regulatory review before any product can be commercialized.View Compass Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
